

29 August 2025

# FY2026 Full Year Guidance

**Bioxyne Limited (ASX: BXN)** (Bioxyne or Company), is pleased to provide full year FY2026 revenue guidance of \$65,000,000 – \$75,000,000, and EBITDA guidance of \$11,500,000 – 13,500,000.

# **Key Highlights:**

- Budgeting continued growth in BLS's Australian medical cannabis business with new contract wins and existing clients increasing forecast order volumes.
- Execution of new manufacturing and supply contracts with large Australian distributors and clinics.
- Rapid expansion into international markets, including maiden contract for \$5.8m into Germany. Purchase orders received.
- First German delivery increased to 1,550kg (up from 580kg), initial shipment scheduled for September 2025, with a second shipment planned for November 2025.

#### **Positive Outlook for FY2026**

Bioxyne is positioned for significant growth in FY2026, attributable to further expansion of its business in Australia and entry into new high-growth opportunity markets including the UK, Germany and other EU countries.

Contract manufacturing services provided the key driver of growth for the business in FY2025, with Pastilles, Flower packing, and Liquids (vape and oral mucosal oils) each representing roughly a third of revenues. Resale of flower API and GMP packed final product is expected to contribute substantially to growth in FY26.


This announcement has been approved for release by the Board.

For further information, please contact:

Bioxyne Limited Investor Relations

Email: info@bioxyne.com Phone: +61 2 9078 8180









## **About Bioxyne Limited:**

Bioxyne Limited is a licensed Australian pharmaceutical and healthcare company manufacturing and distributing novel medicines, health products and active pharmaceutical ingredients including medicinal cannabis, MDMA, and Psilocybin.

https://bioxyne.com

#### **About Bioxyne**

**Bioxyne Limited (ASX:BXN)** is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

## **About Breathe Life Sciences (BLS)**

**Breathe Life Sciences ("BLS")** is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company's corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, lifestyle products, functional mushrooms and nootropics, and prescription medicines in Australia.
- b) Contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe.
- c) Contract / white label manufacture of consumer health products for brands in Japan, UK and Europe in company-owned facilities.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®
  - United Kingdom: drwatsoncbd.com





■ Japan: nolcbn.com

• UK / EU: <u>breathelifesciences.com</u>

f) Export and supply of medicinal cannabis products and manufacturing services to UK and European markets.

**Corporate:** bioxyne.com

Australia: bls.com.au

International: <u>breathelifesciences.com</u>

